Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Business Wire
Company plans to engage with FDA based on interim data from the Phase 2 HELIOS clinical trial demonstrating improvements in pancreatic function, glycemic control, and vision in participants with Wolfram syndrome treated with AMX0035; topline data from all 12 participants at Week 24 anticipated in fall of 2024Interim analysis from the ORION study of AMX0035 in progressive supranuclear palsy continues to be expected in mid-2025Amylyx expects to initiate clinical trial of AMX0114 in ALS in the second half of 2024Cash, cash equivalents and short-term investments of $373.3 million at March 31, 2024 provides expected cash runway into 2026Management to host conference call and webcast today at 8:00 a.m. Eastern Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.“As an organization deeply committed to ending the suffering caused by neurodegenerative disea
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Eli Lilly adds ALS drug prospect with QurAlis deal [Yahoo! Finance]Yahoo! Finance
- Amyotrophic Lateral Sclerosis Market On Track For USD 1,271.6 Mn Revenue By 2033, Growing At 6.5% CAGR | Dimension Market Research [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) had its price target lowered by analysts at Mizuho from $4.00 to $3.00. They now have a "neutral" rating on the stock.MarketBeat
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
AMLX
Earnings
- 5/9/24 - Miss
AMLX
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- 5/15/24 - Form 144
- AMLX's page on the SEC website